Drug Patents Expiring in 2040

1. Agamree patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11382922 CATALYST PHARMS Aqueous oral pharmaceutical suspension compositions
Jul, 2040

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11471471 CATALYST PHARMS Aqueous oral pharmaceutical suspension compositions
Mar, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 26, 2028
Orphan Drug Exclusivity(ODE-450) Oct 26, 2030

Drugs and Companies using VAMOROLONE ingredient

NCE-1 date: 27 October, 2027

Market Authorisation Date: 26 October, 2023

Treatment: Treatment of duchenne muscular dystrophy

Dosage: SUSPENSION

More Information on Dosage

AGAMREE family patents

Family Patents

2. Airduo Digihaler patent expiration

AIRDUO DIGIHALER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11969544

(Pediatric)

TEVA PHARM Inhalers and airflow adaptors therefor
Feb, 2040

(15 years from now)

US11344685

(Pediatric)

TEVA PHARM Drug delivery device with electronics
Mar, 2040

(15 years from now)

US11439777 TEVA PHARM Drug delivery device with electronics
May, 2040

(15 years from now)

US11464923 TEVA PHARM Inhaler system
Jun, 2040

(15 years from now)

US11173259 TEVA PHARM Drug delivery device with electronics and power management
Jul, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-61) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 12 July, 2019

Treatment: NA

Dosage: POWDER

More Information on Dosage

AIRDUO DIGIHALER family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Airduo Respiclick patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11969544

(Pediatric)

TEVA PHARM Inhalers and airflow adaptors therefor
Feb, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 27, 2020
M(M-61) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 12 July, 2019

Treatment: NA

Dosage: POWDER

More Information on Dosage

AIRDUO RESPICLICK family patents

Family Patents

4. Ameluz patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11235169 BIOFRONTERA Illumination device for photodynamic therapy, method for treating a skin disease and method for operating an illumination device
Oct, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 10, 2019

Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient

Market Authorisation Date: 10 May, 2016

Treatment: Topical lesion-directed and field-directed treatment of actinic keratosis of the face and scalp with photodynamic therapy by positioning an illumination device in an appropriate distance and illuminat...

Dosage: GEL

More Information on Dosage

AMELUZ family patents

Family Patents

5. Armonair Digihaler patent expiration

ARMONAIR DIGIHALER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11969544

(Pediatric)

TEVA PHARM Inhalers and airflow adaptors therefor
Feb, 2040

(15 years from now)

US11344685

(Pediatric)

TEVA PHARM Drug delivery device with electronics
Mar, 2040

(15 years from now)

US11439777 TEVA PHARM Drug delivery device with electronics
May, 2040

(15 years from now)

US11464923 TEVA PHARM Inhaler system
Jun, 2040

(15 years from now)

US11173259 TEVA PHARM Drug delivery device with electronics and power management
Jul, 2040

(15 years from now)

US11439777

(Pediatric)

TEVA PHARM Drug delivery device with electronics
Nov, 2040

(15 years from now)

US11464923

(Pediatric)

TEVA PHARM Inhaler system
Dec, 2040

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 08 April, 2022

Treatment: NA

Dosage: POWDER

More Information on Dosage

ARMONAIR DIGIHALER family patents

Family Patents

6. Armonair Respiclick patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11969544

(Pediatric)

TEVA PHARM Inhalers and airflow adaptors therefor
Feb, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 27, 2020
New Patient Population(NPP) Jul 09, 2024
New Strength(NS) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 08 April, 2022

Treatment: NA

Dosage: POWDER

More Information on Dosage

ARMONAIR RESPICLICK family patents

Family Patents

7. Auvelity patent expiration

AUVELITY's oppositions filed in EPO
Can you believe AUVELITY received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10780064 AXSOME Bupropion as a modulator of drug activity
Jan, 2040

(15 years from now)

US10925842 AXSOME Bupropion as a modulator of drug activity
Jan, 2040

(15 years from now)

US10940124 AXSOME Bupropion as a modulator of drug activity
Jan, 2040

(15 years from now)

US10966942 AXSOME Bupropion as a modulator of drug activity
Jan, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 18, 2025

Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient

Market Authorisation Date: 18 August, 2022

Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of AUVELITY before it's drug patent expiration?
More Information on Dosage

AUVELITY family patents

Family Patents

8. Ayvakit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11964980 BLUEPRINT MEDICINES Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1- f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
Apr, 2040

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11999744 BLUEPRINT MEDICINES Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
Apr, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-863) Jun 16, 2024
New Indication(I-864) Jun 16, 2024
New Chemical Entity Exclusivity(NCE) Jan 09, 2025
New Indication(I-912) May 22, 2026
Orphan Drug Exclusivity(ODE-366) Jan 09, 2027
Orphan Drug Exclusivity(ODE-356) Jun 16, 2028
Orphan Drug Exclusivity(ODE-434) May 22, 2030

Drugs and Companies using AVAPRITINIB ingredient

NCE-1 date: 10 January, 2024

Market Authorisation Date: 16 June, 2021

Treatment: Treatment of advanced systemic mastocytosis, including patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with an associated hematological neoplasm (sm-ahn), and mast cell leu...

Dosage: TABLET

More Information on Dosage

AYVAKIT family patents

Family Patents

9. Bynfezia Pen patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11246991 SUN PHARM Electrolysis-resistant coupling assembly for valves
Nov, 2040

(15 years from now)

US11534553 SUN PHARM Method of injecting octreotide acetate into the body
Nov, 2040

(15 years from now)

US11052196 SUN PHARM Method of injecting octreotide acetate into the body
Nov, 2040

(15 years from now)




Drugs and Companies using OCTREOTIDE ACETATE ingredient

Market Authorisation Date: 27 September, 2024

Treatment: Method of treating severe diarrhea and flushing episodes associated with metastatic carcinoid tumors

Dosage: SOLUTION

More Information on Dosage

BYNFEZIA PEN family patents

Family Patents

10. Cabtreo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11389467 BAUSCH Topical compositions
Dec, 2040

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 20, 2026

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE ingredient

Market Authorisation Date: 20 October, 2023

Treatment: Topical treatment of acne vulgaris in adult and pediatric patients 12 years of age and older

Dosage: GEL

More Information on Dosage

CABTREO family patents

Family Patents

11. Caplyta patent expiration

Can you believe CAPLYTA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12090155 INTRA-CELLULAR Methods
Jul, 2040

(15 years from now)

US11753419 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders
Dec, 2040

(16 years from now)

US12122792 INTRA-CELLULAR Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders
Dec, 2040

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-882) Dec 17, 2024
New Chemical Entity Exclusivity(NCE) Dec 20, 2024

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

NCE-1 date: 21 December, 2023

Market Authorisation Date: 22 April, 2022

Treatment: Treatment of depressive episodes or major depressive episodes associated with bipolar ii disorder; Treatment of schizophrenia by inhibiting the 5-ht2a receptor, inhibiting the serotonin transporter, a...

Dosage: CAPSULE

More Information on Dosage

CAPLYTA family patents

Family Patents

12. Carnexiv patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11529357 LUNDBECK PHARMS LLC Injectable carbamazepine composition essentially free of 10-bromo-carbamazepine
Jan, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Oct 07, 2023
Orphan Drug Exclusivity(ODE-124) Oct 07, 2023

Drugs and Companies using CARBAMAZEPINE ingredient

Market Authorisation Date: 07 October, 2016

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

CARNEXIV family patents

Family Patents

13. Daybue patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11370755 ACADIA PHARMS INC Compositions of trofinetide
Aug, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 10, 2028
Orphan Drug Exclusivity(ODE-425) Mar 10, 2030

Drugs and Companies using TROFINETIDE ingredient

NCE-1 date: 11 March, 2027

Market Authorisation Date: 10 March, 2023

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

DAYBUE family patents

Family Patents

14. Elucirem patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11590246 GUERBET Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process
Jan, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 21, 2027

Drugs and Companies using GADOPICLENOL ingredient

NCE-1 date: 21 September, 2026

Market Authorisation Date: 21 September, 2022

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

ELUCIREM family patents

Family Patents

15. Emerphed patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11464752 NEXUS Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
May, 2040

(15 years from now)

US11241400 NEXUS Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
May, 2040

(15 years from now)

US11571398 NEXUS Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
May, 2040

(15 years from now)

US11478436 NEXUS Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
May, 2040

(15 years from now)

US11090278 NEXUS Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
May, 2040

(15 years from now)




Drugs and Companies using EPHEDRINE SULFATE ingredient

Market Authorisation Date: 28 February, 2023

Treatment: Use of ephedrine sulfate for treating hypotension

Dosage: SOLUTION

How can I launch a generic of EMERPHED before it's drug patent expiration?
More Information on Dosage

EMERPHED family patents

Family Patents

16. Ephedrine Sulfate patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12029710 ENDO OPERATIONS Ephedrine compositions and methods
Jan, 2040

(15 years from now)

US10869845 ENDO OPERATIONS Ephedrine compositions and methods
Jan, 2040

(15 years from now)




Drugs and Companies using EPHEDRINE SULFATE ingredient

Market Authorisation Date: 22 April, 2022

Treatment: Treatment of clinically important hypotension occurring in the setting of anesthesia

Dosage: SOLUTION

How can I launch a generic of EPHEDRINE SULFATE before it's drug patent expiration?
More Information on Dosage

EPHEDRINE SULFATE family patents

Family Patents

17. Eprontia patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11911362 AZURITY Compositions and methods for treating epilepsy, seizures and other conditions
Aug, 2040

(15 years from now)

US11633374 AZURITY Compositions and methods for treating epilepsy, seizures and other conditions
Aug, 2040

(15 years from now)

US11433046 AZURITY Compositions and methods for treating epilepsy, seizures and other conditions
Aug, 2040

(15 years from now)

US11826343 AZURITY Compositions and methods for treating epilepsy, seizures and other conditions
Aug, 2040

(15 years from now)




Drugs and Companies using TOPIRAMATE ingredient

Market Authorisation Date: 05 November, 2021

Treatment: Indicated for the preventive treatment of migraine in patients 12 years and older

Dosage: SOLUTION

How can I launch a generic of EPRONTIA before it's drug patent expiration?
More Information on Dosage

EPRONTIA family patents

Family Patents

18. Epsolay patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11865100 GALDERMA LABS LP Method for treatment of rosacea in patients aged 65 years and older
Feb, 2040

(15 years from now)

US10933046 GALDERMA LABS LP Method for treatment of rosacea in patients aged 65 years and older
Feb, 2040

(15 years from now)

US11986456 GALDERMA LABS LP Method for treatment of rosacea
Feb, 2040

(15 years from now)

US11877997 GALDERMA LABS LP Method for providing early onset of action in the treatment of rosacea
Feb, 2040

(15 years from now)

US10945987 GALDERMA LABS LP Method for providing early onset of action in the treatment of rosacea
Feb, 2040

(15 years from now)

US11541026 GALDERMA LABS LP Method for treatment of rosacea
Feb, 2040

(15 years from now)

US11426378 GALDERMA LABS LP Method for long-term treatment of rosacea
Aug, 2040

(15 years from now)

US11628155 GALDERMA LABS LP Method for therapeutic treatment of rosacea
Dec, 2040

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 22, 2025

Drugs and Companies using BENZOYL PEROXIDE ingredient

Market Authorisation Date: 22 April, 2022

Treatment: Topical treatment of inflammatory lesions of rosacea in adults 65 years of age and older; Topical treatment of rosacea; Topical treatment of inflammatory lesions of rosacea in adults 18 years of age a...

Dosage: CREAM

More Information on Dosage

EPSOLAY family patents

Family Patents

19. Erleada patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11963952 JANSSEN BIOTECH Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
Jan, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-808) Sep 17, 2022
New Chemical Entity Exclusivity(NCE) Feb 14, 2023

Drugs and Companies using APALUTAMIDE ingredient

NCE-1 date: 14 February, 2022

Market Authorisation Date: 14 February, 2018

Treatment: Treatment of metastatic castration sensitive prostate cancer

Dosage: TABLET

How can I launch a generic of ERLEADA before it's drug patent expiration?
More Information on Dosage

ERLEADA family patents

Family Patents

20. Farxiga patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11826376

(Pediatric)

ASTRAZENECA AB Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same
Jan, 2040

(15 years from now)

US11903955 ASTRAZENECA AB Methods of treating heart failure with reduced ejection fraction
Mar, 2040

(15 years from now)

US10973836 ASTRAZENECA AB Methods of treating heart failure with reduced ejection fraction
Mar, 2040

(15 years from now)

US10973836

(Pediatric)

ASTRAZENECA AB Methods of treating heart failure with reduced ejection fraction
Sep, 2040

(15 years from now)

US11903955

(Pediatric)

ASTRAZENECA AB Methods of treating heart failure with reduced ejection fraction
Sep, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-157) Mar 11, 2018
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
M(M-212) Oct 20, 2020
M(M-238) Feb 22, 2022
New Indication(I-841) Oct 18, 2022
New Indication(I-834) May 05, 2023
New Indication(I-857) Apr 30, 2024
M(M-298) May 08, 2026
New Patient Population(NPP) Jun 12, 2027
Pediatric Exclusivity(PED) Dec 12, 2027

Drugs and Companies using DAPAGLIFLOZIN ingredient

NCE-1 date: 12 December, 2026

Market Authorisation Date: 08 January, 2014

Treatment: Reduce the risk of cardiovascular death and worsening heart failure in adults with heart failure with reduced ejection fraction, without type ii diabetes, and having an hba1c of < 5.7%; Reduction of t...

Dosage: TABLET

How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage

FARXIGA family patents

Family Patents

21. Fyarro patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11497737 AADI Pharmaceutical compositions of albumin and rapamycin
Oct, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 22, 2024
Orphan Drug Exclusivity(ODE-386) Nov 22, 2028

Drugs and Companies using SIROLIMUS ingredient

Market Authorisation Date: 22 November, 2021

Treatment: NA

Dosage: POWDER

More Information on Dosage

FYARRO family patents

Family Patents

22. Gemtesa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12102638 UROVANT Use of vibegron to treat overactive bladder
Mar, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 23, 2025

Drugs and Companies using VIBEGRON ingredient

NCE-1 date: 23 December, 2024

Market Authorisation Date: 23 December, 2020

Treatment: Treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency

Dosage: TABLET

More Information on Dosage

GEMTESA family patents

Family Patents

23. Genosyl patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11672938 VERO BIOTECH INC Start-up protocols for nitric oxide delivery device
Jul, 2040

(15 years from now)




Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 20 December, 2019

Treatment: A method of delivering nitric oxide to a patient

Dosage: GAS

More Information on Dosage

GENOSYL family patents

Family Patents

24. Hetlioz Lq patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11202770 VANDA PHARMS INC Liquid tasimelteon formulations and methods of use thereof
Dec, 2040

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 01, 2023
Orphan Drug Exclusivity(ODE-329) Dec 01, 2027

Drugs and Companies using TASIMELTEON ingredient

Market Authorisation Date: 01 December, 2020

Treatment: NA

Dosage: SUSPENSION

More Information on Dosage

HETLIOZ LQ family patents

Family Patents

25. Igalmi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12109196 BIOXCEL Non-sedating dexmedetomidine treatment regimens
Jul, 2040

(15 years from now)

US11890272 BIOXCEL Non-sedating dexmedetomidine treatment regimens
Jul, 2040

(15 years from now)

US11998529 BIOXCEL Non-sedating dexmedetomidine treatment regimens
Jul, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 05, 2025

Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient

Market Authorisation Date: 05 April, 2022

Treatment: Acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder by sublingual or buccal administration; Acute treatment of agitation associated with bipolar i or ii disorder by ...

Dosage: FILM

More Information on Dosage

IGALMI family patents

Family Patents

26. Ingrezza patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10940141 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Aug, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 11, 2022
New Indication(I-925) Aug 18, 2026
Orphan Drug Exclusivity(ODE-440) Aug 18, 2030

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

NCE-1 date: 11 April, 2021

Market Authorisation Date: 11 April, 2017

Treatment: Treatment of tardive dyskinesia

Dosage: CAPSULE

How can I launch a generic of INGREZZA before it's drug patent expiration?
More Information on Dosage

INGREZZA family patents

Family Patents

27. Ingrezza Sprinkle patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10940141 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Aug, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-925) Aug 18, 2026

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

Market Authorisation Date: 30 April, 2024

Treatment: Treatment of tardive dyskinesia

Dosage: CAPSULE

More Information on Dosage

INGREZZA SPRINKLE family patents

Family Patents

28. Konvomep patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11771686 AZURITY Compositions and kits for omeprazole suspension
Mar, 2040

(15 years from now)




Drugs and Companies using OMEPRAZOLE; SODIUM BICARBONATE ingredient

Market Authorisation Date: 30 August, 2022

Treatment: Short term treatment of active benign gastric ulcer

Dosage: FOR SUSPENSION

More Information on Dosage

KONVOMEP family patents

Family Patents

29. Lazcluze patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11879013 JANSSEN BIOTECH Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
May, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 19, 2029

Drugs and Companies using LAZERTINIB MESYLATE ingredient

NCE-1 date: 19 August, 2028

Market Authorisation Date: 19 August, 2024

Treatment: First-line treatment of adults with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 l858r substitution mutations, in combination with amivantam...

Dosage: TABLET

More Information on Dosage

LAZCLUZE family patents

Family Patents

30. Liletta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11571328 MEDICINES360 IUD insertion devices
Sep, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 26, 2018
New Indication(I-917) Jun 29, 2026

Drugs and Companies using LEVONORGESTREL ingredient

Market Authorisation Date: 26 February, 2015

Treatment: NA

Dosage: SYSTEM

More Information on Dosage

LILETTA family patents

Family Patents

31. Livmarli patent expiration

Can you believe LIVMARLI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11229647 MIRUM Methods for treating cholestasis
Feb, 2040

(15 years from now)

US11497745 MIRUM Methods for treating cholestasis
Feb, 2040

(15 years from now)

US11918578 MIRUM Methods for treating cholestasis
Feb, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Mar 13, 2026
New Chemical Entity Exclusivity(NCE) Sep 29, 2026
New Indication(I-938) Mar 13, 2027
Orphan Drug Exclusivity(ODE-379) Sep 29, 2028
Orphan Drug Exclusivity(ODE-429) Mar 13, 2030
ODE*(ODE*) Mar 13, 2031
Orphan Drug Exclusivity(ODE-471) Mar 13, 2031
Orphan Drug Exclusivity(ODE-490) Jul 24, 2031

Drugs and Companies using MARALIXIBAT CHLORIDE ingredient

NCE-1 date: 29 September, 2025

Market Authorisation Date: 29 September, 2021

Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs); Treatment of cholestatic pruritus in patients 3 months of age and older with alagille syndrome (algs)

Dosage: SOLUTION

More Information on Dosage

LIVMARLI family patents

Family Patents

32. Lumakras patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11827635 AMGEN INC Solid state forms
May, 2040

(15 years from now)

US11236091 AMGEN INC Solid state forms
May, 2040

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11426404 AMGEN INC Dosing of KRAS inhibitor for treatment of cancers
Sep, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 28, 2026
ODE*(ODE*) May 28, 2028
Orphan Drug Exclusivity(ODE-352) May 28, 2028

Drugs and Companies using SOTORASIB ingredient

NCE-1 date: 28 May, 2025

Market Authorisation Date: 28 May, 2021

Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda-approved test, who have received at least one prior system...

Dosage: TABLET

More Information on Dosage

LUMAKRAS family patents

Family Patents

33. Lumryz patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10925844 AVADEL CNS Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
Feb, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 01, 2026
Orphan Drug Exclusivity(ODE-431) May 01, 2030
Orphan Drug Exclusivity(ODE-494) Oct 16, 2031

Drugs and Companies using SODIUM OXYBATE ingredient

Market Authorisation Date: 01 May, 2023

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE

More Information on Dosage

LUMRYZ family patents

Family Patents

34. Motpoly Xr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11337943 AUCTA Lacosamide pharmaceutical composition and dosage form thereof
Jun, 2040

(15 years from now)

US11883374 AUCTA Lacosamide pharmaceutical composition and dosage form thereof
Jun, 2040

(15 years from now)

US12042474 AUCTA Lacosamide pharmaceutical composition and dosage form thereof
Jun, 2040

(15 years from now)




Drugs and Companies using LACOSAMIDE ingredient

Market Authorisation Date: 04 May, 2023

Treatment: Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and in pediatric patients weighing at least 50 kg; Treatment of partial-onset seizures in adults and in pedia...

Dosage: CAPSULE, EXTENDED RELEASE

More Information on Dosage

MOTPOLY XR family patents

Family Patents

35. Mycapssa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11141457 CHIESI Oral octreotide therapy and contraceptive methods
Dec, 2040

(16 years from now)

US11890316 CHIESI Oral octreotide therapy and contraceptive methods
Dec, 2040

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 26, 2023
Orphan Drug Exclusivity(ODE-474) Jun 26, 2027

Drugs and Companies using OCTREOTIDE ACETATE ingredient

Market Authorisation Date: 26 June, 2020

Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients while avoiding concomitant administration of levonorgestrel

Dosage: CAPSULE, DELAYED RELEASE

More Information on Dosage

MYCAPSSA family patents

Family Patents

36. Nexletol patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11613511 ESPERION THERAPS INC Methods of making bempedoic acid and compositions of the same
Jun, 2040

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11760714 ESPERION THERAPS INC Methods of making bempedoic acid and compositions of the same
Jun, 2040

(15 years from now)

US11926584 ESPERION THERAPS INC Methods of making bempedoic acid and compositions of the same
Jun, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 21, 2025
New Indication(I-943) Mar 22, 2027
New Indication(I-944) Mar 22, 2027

Drugs and Companies using BEMPEDOIC ACID ingredient

NCE-1 date: 22 February, 2024

Market Authorisation Date: 21 February, 2020

Treatment: A method of lowering low-density lipoprotein cholesterol (ldl-c) in a human patient in need thereof comprising administration of bempedoic acid alone or in combination with other lipid lowering therap...

Dosage: TABLET

More Information on Dosage

NEXLETOL family patents

Family Patents

37. Nexlizet patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11613511 ESPERION THERAPS INC Methods of making bempedoic acid and compositions of the same
Jun, 2040

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11926584 ESPERION THERAPS INC Methods of making bempedoic acid and compositions of the same
Jun, 2040

(15 years from now)

US11760714 ESPERION THERAPS INC Methods of making bempedoic acid and compositions of the same
Jun, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 26, 2023
New Chemical Entity Exclusivity(NCE) Feb 21, 2025
New Indication(I-943) Mar 22, 2027
New Indication(I-945) Mar 22, 2027

Drugs and Companies using BEMPEDOIC ACID; EZETIMIBE ingredient

NCE-1 date: 22 February, 2024

Market Authorisation Date: 26 February, 2020

Treatment: A method of lowering low-density lipoprotein cholesterol (ldl-c) in a human patient in need thereof comprising administration of bempedoic acid alone or in combination with other lipid lowering therap...

Dosage: TABLET

More Information on Dosage

NEXLIZET family patents

Family Patents

38. Ojjaara patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11963962 GLAXOSMITHKLINE Platelet count-agnostic methods of treating myelofibrosis
Dec, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 15, 2028
Orphan Drug Exclusivity(ODE-441) Sep 15, 2030

Drugs and Companies using MOMELOTINIB DIHYDROCHLORIDE ingredient

NCE-1 date: 16 September, 2027

Market Authorisation Date: 15 September, 2023

Treatment: For the treatment of intermediate or high-risk myelofibrosis in subjects having a baseline platelet count of less than 50 billion/l

Dosage: TABLET

More Information on Dosage

OJJAARA family patents

Family Patents

39. Opzelura patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11590138 INCYTE CORP Topical treatment of vitiligo by a jak inhibitor
Jun, 2040

(15 years from now)

US11510923 INCYTE CORP Ruxolitinib formulation for reduction of itch in atopic dermatitis
Sep, 2040

(15 years from now)

US11590137 INCYTE CORP Ruxolitinib formulation for reduction of itch in atopic dermatitis
Sep, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 21, 2024
New Indication(I-896) Jul 18, 2025
Pediatric Exclusivity(PED) Jan 18, 2026

Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient

Market Authorisation Date: 21 September, 2021

Treatment: For the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older, in the absence of phototherapy, wherein the vitiligo affects at least one of the lower ext...

Dosage: CREAM

More Information on Dosage

OPZELURA family patents

Family Patents

40. Oriahnn (copackaged) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11690845 ABBVIE Methods of administering elagolix
Aug, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 29, 2023
New Chemical Entity Exclusivity(NCE) Jul 23, 2023

Drugs and Companies using ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM ingredient

NCE-1 date: 23 July, 2022

Market Authorisation Date: 29 May, 2020

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) using 300 mg elagolix while co-administering omeprazole

Dosage: CAPSULE

How can I launch a generic of ORIAHNN (COPACKAGED) before it's drug patent expiration?
More Information on Dosage

ORIAHNN (COPACKAGED) family patents

Family Patents

41. Orilissa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11690845 ABBVIE Methods of administering elagolix
Aug, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 23, 2023

Drugs and Companies using ELAGOLIX SODIUM ingredient

NCE-1 date: 23 July, 2022

Market Authorisation Date: 23 July, 2018

Treatment: Management of moderate to severe pain associated with endometriosis using 150 mg or 200 mg elagolix while co-administering omeprazole

Dosage: TABLET

How can I launch a generic of ORILISSA before it's drug patent expiration?
More Information on Dosage

ORILISSA family patents

Family Patents

42. Pemazyre patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11628162 INCYTE CORP Methods of treating cancer with an FGFR inhibitor
Aug, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 17, 2025
New Indication(I-899) Aug 26, 2025
Orphan Drug Exclusivity(ODE-292) Apr 17, 2027
Orphan Drug Exclusivity(ODE-404) Aug 26, 2029

Drugs and Companies using PEMIGATINIB ingredient

NCE-1 date: 17 April, 2024

Market Authorisation Date: 17 April, 2020

Treatment: Treatment of relapsed or refractory myeloid/lymphoid neoplasms with fgfr1 rearrangement by administering pemigatinib while avoiding the concomitant use of strong and moderate cyp3a inhibitors

Dosage: TABLET

More Information on Dosage

PEMAZYRE family patents

Family Patents

43. Proair Digihaler patent expiration

PROAIR DIGIHALER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11439777 TEVA BRANDED PHARM Drug delivery device with electronics
May, 2040

(15 years from now)

US11464923 TEVA BRANDED PHARM Inhaler system
Jun, 2040

(15 years from now)

US11173259 TEVA BRANDED PHARM Drug delivery device with electronics and power management
Jul, 2040

(15 years from now)




Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 21 December, 2018

Treatment: NA

Dosage: POWDER, METERED

More Information on Dosage

PROAIR DIGIHALER family patents

Family Patents

44. Qdolo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103452 ATHENA Tramadol hydrochloride solution
Sep, 2040

(15 years from now)

US11752103 ATHENA Tramadol hydrochloride solution
Sep, 2040

(15 years from now)




Drugs and Companies using TRAMADOL HYDROCHLORIDE ingredient

Market Authorisation Date: 01 September, 2020

Treatment: Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate

Dosage: SOLUTION

More Information on Dosage

QDOLO family patents

Family Patents

45. Qinlock patent expiration

Can you believe QINLOCK received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12023325 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(15 years from now)

US12059411 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(15 years from now)

US12059410 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(15 years from now)

US11266635 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(15 years from now)

US11344536 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(15 years from now)

US11813251 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(15 years from now)

US11426390 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(15 years from now)

US11576904 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(15 years from now)

US11433056 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(15 years from now)

US10966966 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(15 years from now)

US11529336 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(15 years from now)

US11534432 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(15 years from now)

US12023327 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(15 years from now)

US12023326 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(15 years from now)

US11793795 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
Dec, 2040

(16 years from now)

US11850240 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
Dec, 2040

(16 years from now)

US11911370 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
Dec, 2040

(16 years from now)

US11576903 DECIPHERA PHARMS Amorphous kinase inhibitor formulations and methods of use thereof
Dec, 2040

(16 years from now)

US11801237 DECIPHERA PHARMS Amorphous kinase inhibitor formulations and methods of use thereof
Dec, 2040

(16 years from now)

US11896585 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
Dec, 2040

(16 years from now)

US11850241 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
Dec, 2040

(16 years from now)

US12023328 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
Dec, 2040

(16 years from now)

US11969415 DECIPHERA PHARMS (methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
Dec, 2040

(16 years from now)

US11903933 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
Dec, 2040

(16 years from now)

US11844788 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
Dec, 2040

(16 years from now)

US11395818 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
Dec, 2040

(16 years from now)

US12064422 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
Dec, 2040

(16 years from now)

US11612591 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
Dec, 2040

(16 years from now)

US11185535 DECIPHERA PHARMS Amorphous kinase inhibitor formulations and methods of use thereof
Dec, 2040

(16 years from now)

US11918564 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
Dec, 2040

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 15, 2025
Orphan Drug Exclusivity(ODE-298) May 15, 2027

Drugs and Companies using RIPRETINIB ingredient

NCE-1 date: 15 May, 2024

Market Authorisation Date: 15 May, 2020

Treatment: Treatment of advanced gastrointestinal stromal tumor in patients previously administered imatinib; Treatment of gastrointestinal stromal tumors in patients suffering from palmar-plantar erythrodysesth...

Dosage: TABLET

More Information on Dosage

QINLOCK family patents

Family Patents

46. Recorlev patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11903940 STRONGBRIDGE Methods of treating disease with levoketoconazole
Mar, 2040

(15 years from now)

US11020393 STRONGBRIDGE Methods of treating disease with levoketoconazole
Mar, 2040

(15 years from now)

US11278547 STRONGBRIDGE Methods of treating disease with levoketoconazole
Mar, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-385) Dec 30, 2028

Drugs and Companies using LEVOKETOCONAZOLE ingredient

Market Authorisation Date: 30 December, 2021

Treatment: During levoketoconazole dosage titration for the treatment of cushing's syndrome in patients who concomitantly use an oct2 substrate, monitoring the subject for a dose limiting event and adjusting the...

Dosage: TABLET

More Information on Dosage

RECORLEV family patents

Family Patents

47. Relyvrio patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11583542 AMYLYX Compositions of bile acids and phenylbutyrate compounds
Jul, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 29, 2027
Orphan Drug Exclusivity(ODE-411) Sep 29, 2029

Drugs and Companies using SODIUM PHENYLBUTYRATE; TAURURSODIOL ingredient

NCE-1 date: 29 September, 2026

Market Authorisation Date: 29 September, 2022

Treatment: NA

Dosage: FOR SUSPENSION

More Information on Dosage

RELYVRIO family patents

Family Patents

48. Reyvow patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12071423 ELI LILLY AND CO Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate
Jul, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 31, 2025

Drugs and Companies using LASMIDITAN SUCCINATE ingredient

NCE-1 date: 01 February, 2024

Market Authorisation Date: 31 January, 2020

Treatment: NA

Dosage: TABLET

More Information on Dosage

REYVOW family patents

Family Patents

49. Scemblix patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11407735 NOVARTIS Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
May, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 29, 2026
ODE*(ODE*) Oct 29, 2028
Orphan Drug Exclusivity(ODE-381) Oct 29, 2028
Orphan Drug Exclusivity(ODE-382) Oct 29, 2028

Drugs and Companies using ASCIMINIB HYDROCHLORIDE ingredient

NCE-1 date: 29 October, 2025

Market Authorisation Date: 29 October, 2021

Treatment: NA

Dosage: TABLET

More Information on Dosage

SCEMBLIX family patents

Family Patents

50. Sofdra patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11566000 BOTANIX SB Crystalline form of sofpironium bromide and preparation method thereof
May, 2040

(15 years from now)

US11584715 BOTANIX SB Crystalline form of sofpironium bromide and preparation method thereof
May, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 20, 2029

Drugs and Companies using SOFPIRONIUM BROMIDE ingredient

NCE-1 date: 20 June, 2028

Market Authorisation Date: 18 June, 2024

Treatment: NA

Dosage: GEL, METERED

More Information on Dosage

SOFDRA family patents

Family Patents

51. Spravato patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11883526 JANSSEN PHARMS Esketamine for the treatment of depression
Feb, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-840) Jul 31, 2023
NCE*(NCE*) Mar 05, 2024

Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 05 March, 2019

Treatment: Treatment of trd with nasally administered esketamine in conjunction with an oad in a patient who has missed a dose during the maintenance phase and had worsening of depression symptom by returning to...

Dosage: SPRAY

How can I launch a generic of SPRAVATO before it's drug patent expiration?
More Information on Dosage

SPRAVATO family patents

Family Patents

52. Sunosi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11986454 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11160779 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11969404 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US10940133 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11839599 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11839598 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11850226 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11850227 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11850228 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11857528 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11986455 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 17, 2024
Orphan Drug Exclusivity(ODE-254) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: 18 June, 2023

Market Authorisation Date: 17 June, 2019

Treatment: Treatment of excessive daytime sleepiness by administering solriamfetol to a subject having no, mild, moderate, or severe renal impairment; Treatment of excessive daytime sleepiness by administering s...

Dosage: TABLET

How can I launch a generic of SUNOSI before it's drug patent expiration?
More Information on Dosage

SUNOSI family patents

Family Patents

53. Sympazan patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11541002 OTTER PHARMS Oral film compositions and dosage forms having precise active dissolution profiles
Jan, 2040

(15 years from now)




Drugs and Companies using CLOBAZAM ingredient

Market Authorisation Date: 01 November, 2018

Treatment: Method of treating seizures

Dosage: FILM

More Information on Dosage

SYMPAZAN family patents

Family Patents

54. Tlando patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12011503 VERITY Fixed dose oral testosterone undecanoate compositions and use thereof
Oct, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 28, 2025

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 28 March, 2022

Treatment: Methods of continuing or discontinuing a dosage regimen of a testosterone undecanoate pharmaceutical composition to a hypogonadal male subject

Dosage: CAPSULE

More Information on Dosage

TLANDO family patents

Family Patents

55. Tymlos patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11255842 RADIUS Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHRP) analog
Jan, 2040

(15 years from now)

US11680942 RADIUS Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) analog
Jan, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 28, 2022
M(M-270) Sep 20, 2024
New Indication(I-907) Dec 19, 2025

Drugs and Companies using ABALOPARATIDE ingredient

NCE-1 date: 28 April, 2021

Market Authorisation Date: 28 April, 2017

Treatment: Use for detecting neutralizing antibodies

Dosage: SOLUTION

How can I launch a generic of TYMLOS before it's drug patent expiration?
More Information on Dosage

TYMLOS family patents

Family Patents

List of large molecules

1. List of Eylea large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US11555176 REGENERON PHARMACEUTICALS, INC. Cell culture medium for eukaryotic cells
Jan, 2040

(15 years from now)

US11439758 REGENERON PHARMACEUTICALS, INC. Devices and methods for precision dose delivery
Jun, 2040

(15 years from now)

US11478588 REGENERON PHARMACEUTICALS, INC. Needle shield grip devices and related methods
Jul, 2040

(15 years from now)

US11793926 REGENERON PHARMACEUTICALS, INC. Medical device packaging and related methods
Jul, 2040

(15 years from now)

US11299532 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(15 years from now)

US11306135 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(15 years from now)

US11459374 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(15 years from now)

US11459373 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(15 years from now)

US11472861 REGENERON PHARMACEUTICALS, INC. Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
Aug, 2040

(15 years from now)

US11485770 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(15 years from now)

US11505593 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(15 years from now)

US11548932 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(15 years from now)

US11753459 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(15 years from now)

US11104715 REGENERON PHARMACEUTICALS, INC. Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
Aug, 2040

(15 years from now)

US11174283 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(15 years from now)

US11186625 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(15 years from now)

US11053280 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(15 years from now)

US11542317 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(15 years from now)

US11535663 REGENERON PHARMACEUTICALS, INC. Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
Aug, 2040

(15 years from now)

US11732025 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(15 years from now)

US11525833 REGENERON PHARMACEUTICALS, INC. Hydrophobic interaction chromatography-coupled native mass spectrometry for antibody analysis
Nov, 2040

(15 years from now)

Ingredients: AFLIBERCEPT